The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the second half of the year? 

This eBook digs into the business side of the biotech, pharma and medtech markets to look hard for any glimmers of hope to sustain us as we crack on with the remainder of the year.



Some M&A activity back on the menu at last
The IPO market hits a 10-year low for the second quarter
Share price performance: have we reached the bottom?
Big medtech share price bloodbath